Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jan 11;263:531–538. doi: 10.1007/s00415-015-8009-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2016

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

PMC Copyright notice

Fig. 2 — On-study T2 hyperintense lesion volume changes in glatiramer acetate vs. untreated patients. Mean (±standard error of the mean) of total cerebral T2 hyperintense lesion volume (T2LV) at baseline and 2-year follow-up. A higher score indicates advancing disease. Both glatiramer acetate (GA) and no disease modifying therapy (noDMT) cohorts showed no significant decreases from baseline to follow-up. The p values in the figure are from Wilcoxon signed rank tests for the within group change over time. Furthermore, when comparing the change in zT2LV between the two groups, no difference was found (Wilcoxon rank sum test, p = 0.40)